In clinical, a significant high ratio of response (R, complete response or partial response) to fluoropyrimidine-based chemotherapy was observed in the CRC patients with MAGI3-high than those of MAGI3-low at mRNA level (86.7% vs. 54.8%, Fig. 7c), indicating MAGI3 correlated with chemotherapy response both in vitro and in vivo. Here, MAGI3 is linked to colorectal carcinoma.